Nuevolution announces license agreement with Merck
Nuevolution A/S announced that it has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development.
Under terms of the agreement, Merck will gain exclusive rights for the further development and commercialization of the compounds. This is the second agreement between Nuevolution and Merck. Nuevolution will receive an undisclosed upfront payment and milestone payments forcertain preclinical, clinical and agreed upon commercial milestones. In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products. Further financial details were not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

FIU scientists discover how arsenic builds up in plant seeds

Unique new antiviral treatment made using sugar
Eckert & Ziegler: Highest quarterly profit in Q2 2010
High-Tech Gruenderfonds invests in agricultural biotechnology startup

Proteomic profiling reveals innovation potential of new antibiotics - Research team intends to use proteomics to accelerate the development of new drugs
Galapagos, Amsterdam Molecular Therapeutics, Netherlands Institute for Brain Research and Vrije Universiteit Amsterdam cooperate

Pangolin the inspiration for medical robot - It could one day reach even the narrowest and most sensitive regions in the body in a minimally invasive and gentle way
Lab21 secures European and USA patents for HCV drug resistance genotyping
OctoPlus appoints Jan Hendrik Egberts as CEO
